- Home
- PRPL vs GNLX Comparison
PRPL vs GNLX Comparison
Compare PRPL & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRPL | GNLX |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1M | 110.4M |
| IPO Year | 2015 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PRPL | GNLX |
|---|---|---|
| Price | $3.27 | $2.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $0.65 | ★ $17.25 |
| AVG Volume (30 Days) | 24.8K | ★ 297.3K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 152.75 | 9.47 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $468,725,000.00 | $8,000.00 |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $6.68 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.28 | $2.29 |
| 52 Week High | $10.00 | $8.54 |
Technical Indicators
Market Signals| Indicator | PRPL | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 30.41 | 38.62 |
| Support Level | $0.51 | $2.33 |
| Resistance Level | $10.00 | $2.97 |
| Average True Range (ATR) | 0.29 | 0.16 |
| MACD | -0.21 | -0.02 |
| Stochastic Oscillator | 0.80 | 11.61 |
Price Performance
Historical ComparisonAbout PRPL Purple Innovation Inc.
Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.